API

We offer a full range of peptides globally, such as Liraglutide, Semaglutide and Exenatide for diabetes; Terlipressin, Desmopressin and Linaclotide for digestive tract and metabolic system; Ganirelix, Cetrorelix and Atosiban for obstetrics and gynecology, etc.

Facilities

Hybio Pharmaceutical (Wuhan) Co., Ltd is a subsidiary of Hybio Group, it locates in Huangpi district of Wuhan City with around 200 employees in total. With a total investment over US$1 billion, an overall construction area of 250,000 square meters under cGMP standard, Hybio Wuhan was completed and put into use in second half of 2018. As a new factory, it consists of four parts including Peptide APIs site, Oral Solid Dosage site, Biopharma site and Service Center site. Equipped with the comprehensive facilities, Hybio Wuhan provides full range of peptide products and all-round services to satisfy customers internationally.

GMP 

Over the years, Hybio has passed inspections from overseas and Chinese authorities and customers for an accumulated 150 times, covering its Shenzhen API site, Wuhan API site and Pingshan FDF site.